A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Liu, Joyce
  • Ray-Coquard, Isabelle Laure
  • Selle, Frédéric
  • Poveda, Andres
  • Cibula, David
  • Hirte, Holger
  • Raspagliesi, Francesco
  • Gladieff, Laurence
  • Harter, Philipp
  • Schiavetto, Ilaria
  • Tabah-Fisch, Isabelle Marie
  • MacBeath, Gavin
  • Czibere, Akos Gabor
  • Naumann, R Wendel
  • Coleman, Robert L
  • Vergote, Ignace
  • Pujade-Lauraine, Eric

publication date

  • May 20, 2014